ArticleFrontiers in immunology2024
IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Junzhang Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papertrialcites it